middle.news
LTR Pharma Accelerates ED Treatment with Breakthrough Nasal Spray Data and $34M Cash Boost
7:03pm on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
LTR Pharma Accelerates ED Treatment with Breakthrough Nasal Spray Data and $34M Cash Boost
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
SPONTAN® nasal spray achieves 470% faster absorption than oral ED tablets
Strategic joint venture launched with Restorative Sexual Health Clinic for telehealth services
Agreements secured with Men's Health Downunder and Symbion for pharmacy distribution
Completed $25 million capital raise, ending quarter with $34.1 million cash
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
LTR PHARMA (ASX:LTP)
OPEN ARTICLE